An initial pooled analysis of 70 cases with BRAF V600E mutations from the CRYSTAL and OPUS randomized clinical trials found that the addition of cetuximab to first-line chemotherapy was possibly associated with a nonsignificant trend toward improved progression-free survival (PFS) and OS for BRAF V600E -mutant metastatic CRC, although inferior OS was observed across treatment arms in comparison to BRAF -wild-type patients. 28 However, a large meta-analysis of 463 BRAF V600E tumors from one Phase II and nine Phase III trials of
1
—
—